Literature DB >> 11411756

Fibrosis and ischemia: the real risks in hypertensive heart disease.

E D Frohlich1.   

Abstract

The increased cardiovascular morbidity and mortality in hypertension are related to the target organs (ie, heart, brain, kidneys) involvement from vascular disease. Left ventricular hypertrophy (LVH), the major expression of cardiac involvement, is both a structural and functional adaptation to the afterload imposed by the vascular disease. Without this adaptation, cardiac failure would result much earlier in the natural history of hypertensive heart disease (HHD). However, LVH imposes an independent risk that is even greater than the risk associated with the height of systolic or diastolic pressure. The mechanisms that explain this risk have not been defined precisely; several have been postulated. Among these are the following: 1) coronary hemodynamic alterations associated with HHD (ie, increased coronary vascular and minimal vascular resistance, reduced coronary blood flow and flow reserve, and increased blood viscosity); 2) enhanced predisposition for lethal cardiac arrhythmias, cardiac failure, and accelerated atherosclerosis of the coronary arteries (with exacerbation of the ischemia); and 3) collagen deposition and ventricular fibrosis. From the earliest controlled therapeutic trials, deaths from stroke and coronary heart disease were significantly reduced. However, more recent data have indicated that the prevalence of cardiac failure (CHF) continues to rise progressively. The nature of the CHF is no longer primarily from systolic dysfunction, but is now chiefly from diastolic dysfunction. Diastolic dysfunction occurs primarily in the elderly hypertensive patient or in the patient with ischemic heart disease, both of which are associated with increased collagen deposition. Indeed, these effects continue to be suggested by the data from the Framingham Heart Study as well as NHANES-III that indicate CHF is the most common diagnosis occurring in hospitalized patients over 65 years of age. In this report, both experimental and clinical evidence demonstrating that increased ventricular fibrosis occurs in the spontaneously hypertensive rats and in hypertensive patients are provided, and that treatment with the newer antihypertensive agents reduce ventricular hydroxyproline (ie, collagen) content while, at the same time, improve coronary hemodynamics.

Entities:  

Mesh:

Year:  2001        PMID: 11411756     DOI: 10.1016/s0895-7061(01)02088-x

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  13 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2002

2.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2001-10

Review 3.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

4.  Hypertension research program at ochsner: a program in translational research.

Authors:  Edward Frohlich
Journal:  Ochsner J       Date:  2002

5.  Variability in electrophysiological properties and conducting obstacles controls re-entry risk in heterogeneous ischaemic tissue.

Authors:  Brodie A J Lawson; Rafael S Oliveira; Lucas A Berg; Pedro A A Silva; Kevin Burrage; Rodrigo Weber Dos Santos
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2020-05-25       Impact factor: 4.226

6.  Coronary circulation in hypertension and aging: an experimental study.

Authors:  Dinko Susic; Jasmina Varagic; Edward D Frohlich
Journal:  Ochsner J       Date:  2008

7.  A new model of congestive heart failure in rats.

Authors:  Jiqiu Chen; Elie R Chemaly; Li Fan Liang; Thomas J LaRocca; Elisa Yaniz-Galende; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-17       Impact factor: 4.733

8.  Transforming growth factor beta-1 and incidence of heart failure in older adults: the Cardiovascular Health Study.

Authors:  Nicole L Glazer; Elizabeth M Macy; Thomas Lumley; Nicholas L Smith; Alex P Reiner; Bruce M Psaty; George L King; Russell P Tracy; David S Siscovick
Journal:  Cytokine       Date:  2012-08-09       Impact factor: 3.861

9.  Hypertensive Cardiovascular and Renal Disease and Target Organ Damage: Lessons from Animal Models.

Authors:  Dinko Susic; Edward D Frohlich
Journal:  Cardiorenal Med       Date:  2011-06-25       Impact factor: 2.041

Review 10.  Anti-hypertensive drugs have different effects on ventricular hypertrophy regression.

Authors:  Celso Ferreira Filho; Luiz Carlos de Abreu; Vitor E Valenti; Marcelo Ferreira; Adriano Meneghini; José Alexandre Silveira; Andrés R Pérez Riera; Eduardo Colombari; Neif Murad; Paulo Roberto Santos-Silva; Lovian José Henrique Pereira da Silva; Luiz Carlos Marques Vanderlei; Tatiana D Carvalho; Celso Ferreira
Journal:  Clinics (Sao Paulo)       Date:  2010-07       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.